BYFAVO (remimazolam)(Information obtained and shared from product website https://byfavo.com/ )

Byfavo®: A Short-Acting Sedative for Procedures 30 Minutes or Less

 

Rapid Onset of Action

Onset of sedative effects of 1.0-1.5 minutes1,* and median time to peak sedation was 3.0-3.5 minutes after initial 5 mg dose.2

 

Rapid Offset of Action

Median time to fully alert was 11.0-14.0 minutes following last dose.2

 

Rapidly Metabolized

CYP450-independent metabolism with no active metabolite resulting in a terminal half-life of 37-53 minutes.2

The soft drug approach is a strategy where compounds are specifically designed to be vulnerable to rapid biotransformation into inactive metabolites.3,5

Mechanism of Action

Byfavo is a benzodiazepine. Like other benzodiazepines, Byfavo binds to GABAA receptors in the brain, while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. Byfavo, like other benzodiazepines, did not show clear selectivity between subtypes of the GABAA receptor.2

Soft, Ester-Based Drug Design

Remimazolam was derived from midazolam.3 The molecular structure of remimazolam differs from midazolam, and all other benzodiazepines, due to the addition of the carboxylic ester linkage.4 The addition of a carboxylic ester linkage creates a “soft drug.”5 The soft drug approach is a strategy where compounds are specifically designed to be vulnerable to rapid biotransformation into inactive metabolites.3,5 This approach was used for the development of remifentanil, a nonhepatically metabolized fentanyl derivative.5,6

byfavo success rate table

Characteristic Benzodiazepine Safety Profile

Established Safety in a Diverse Range of Adult Patients Across 3 Clinical Trials

Common Adverse Reactions Occurring at >2% in Any Treatment Group

Data reflect exposure to Byfavo in 630 ASA I-IV patients pooled from the three placebo-controlled Phase 3 studies.1

 The most common adverse reactions (>10%) in patients receiving Byfavo for procedural sedation were hypotension, hypertension, diastolic hypertension, systolic hypertension, hypoxia, and diastolic hypotension1

Patients receiving Byfavo experienced less hypotension than those receiving placebo with midazolam1

 

https://byfavo.com/dosing-and-administration/